Metabolic Changes in Blood Samples From Patients With Acute Myeloid Leukemia

Study Overview
=================
Brief Summary
-----------------
This research trial studies metabolic changes in blood samples from patients with acute myeloid leukemia. Studying samples of blood from patients with acute myeloid leukemia in the laboratory may help doctors learn more about cancer and the development of drug resistance.

Detailed Description
-----------------
PRIMARY OBJECTIVES: I. To determine the metabolic adaptations that occur following exposure to standard chemotherapeutic agents using peripheral blood mononuclear cells from acute myeloid leukemia (AML) patients. OUTLINE: Patients undergo collection of peripheral blood mononuclear cell (PBMC) samples for analysis via cell isolation, glycolytic flux and oxygen consumption assays, viability assays, and western blot at baseline, 24, 48, and 72 hours after starting chemotherapy.

Official Title
-----------------
A Study of the Metabolic Changes in Leukemia Cells Following Treatment in AML Patients

Conditions
-----------------
Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia

Intervention / Treatment
-----------------
* Other: Cytology Specimen Collection Procedure
* Other: Laboratory Biomarker Analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients scheduled to initiate chemotherapy for either an initial diagnosis of AML or relapsed AML Starting the initial induction phase of therapy Exposure to hydroxyurea is acceptable but must be noted at the time of sample collection Ability to understand and the willingness to sign an institutional review board (IRB)-approved informed consent Exclusion Criteria: Received at least one dose of chemotherapy during the current cycle (excluding hydroxyurea).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Ancillary-Correlative (metabolic changes)<br>Patients undergo collection of PBMC samples for analysis via cell isolation, glycolytic flux and oxygen consumption assays, viability assays, and western blot at baseline, 24, 48, and 72 hours after starting chemotherapy. | Other: Cytology Specimen Collection Procedure<br>* Undergo collection of PBMC samples<br>* Other names: Cytologic Sampling;Other: Laboratory Biomarker Analysis<br>* Undergo metabolic analysis<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glycolytic flux rate | Results will be analyzed using descriptive statistics. Comparison between groups will be done using t-tests or ANOVA procedures. Other inferential statistical analysis will be conducted as appropriate. | Up to 72 hours after starting chemotherapy | 
| Level of fatty acid synthase by western blot | Results will be analyzed using descriptive statistics. Comparison between groups will be done using t-tests or ANOVA procedures. Other inferential statistical analysis will be conducted as appropriate. | Up to 72 hours after starting chemotherapy | 
| Number of mononuclear cells per sample determined by cell isolation | Results will be analyzed using descriptive statistics. Comparison between groups will be done using t-tests or analysis of variance (ANOVA) procedures. Other inferential statistical analysis will be conducted as appropriate. | Up to 72 hours after starting chemotherapy | 
| Oxygen consumption rate | Results will be analyzed using descriptive statistics. Comparison between groups will be done using t-tests or ANOVA procedures. Other inferential statistical analysis will be conducted as appropriate. | Up to 72 hours after starting chemotherapy | 
| Number of viable samples | Results will be analyzed using descriptive statistics. Comparison between groups will be done using t-tests or ANOVA procedures. Other inferential statistical analysis will be conducted as appropriate. | Up to 72 hours after starting chemotherapy | 
| Level of hexokinase by western blot | Results will be analyzed using descriptive statistics. Comparison between groups will be done using t-tests or ANOVA procedures. Other inferential statistical analysis will be conducted as appropriate. | Up to 72 hours after starting chemotherapy | 
| Level of phosphofructokinase-1 by western blot | Results will be analyzed using descriptive statistics. Comparison between groups will be done using t-tests or ANOVA procedures. Other inferential statistical analysis will be conducted as appropriate. | Up to 72 hours after starting chemotherapy | 
| Level of phosphoglycerate mutase by western blot | Results will be analyzed using descriptive statistics. Comparison between groups will be done using t-tests or ANOVA procedures. Other inferential statistical analysis will be conducted as appropriate. | Up to 72 hours after starting chemotherapy | 
| Total level of pyruvate kinase M2 by western blot | Results will be analyzed using descriptive statistics. Comparison between groups will be done using t-tests or ANOVA procedures. Other inferential statistical analysis will be conducted as appropriate. | Up to 72 hours after starting chemotherapy | 
| Level of pyruvate kinase M2 for phospho-T105 by western blot | Results will be analyzed using descriptive statistics. Comparison between groups will be done using t-tests or ANOVA procedures. Other inferential statistical analysis will be conducted as appropriate. | Up to 72 hours after starting chemotherapy | 
| Level of phosphofructokinase-2 by western blot | Results will be analyzed using descriptive statistics. Comparison between groups will be done using t-tests or ANOVA procedures. Other inferential statistical analysis will be conducted as appropriate. | Up to 72 hours after starting chemotherapy |